Imipenem-cilastatin as initial therapy for febrile cancer patients
- PMID: 3532942
- PMCID: PMC180520
- DOI: 10.1128/AAC.30.2.211
Imipenem-cilastatin as initial therapy for febrile cancer patients
Abstract
Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
